Diazepam; Nordiazepam
Diazepam (Valium®, Valrelease) is the second benzodiazepine derivative to have been approved for human usage (1963) and has been one of the most frequently prescribed drugs in the United States. It is administered as an antianxiety agent, muscle relaxant, or anticonvulsant, orally or by intramuscular or intravenous injection, in single doses of 2-20 mg and up to 40 mg daily. Diazepam undergoes N-demethylation to nordiazepam, a metabolite at least as active as its parent. Overdosage with diazepam generally results in drowsiness, ataxia, and muscular weakness. Chronic usage may cause physical dependence, and grand mal seizures can occur upon withdrawal.
3.0 mL Serum from a Red Top Tube in a Plastic Vial
1 week Refrigerated
Do not collect in a Serum Separator Tube (SST or PST)
Let specimen clot for 30 minutes
Centrifuge for 15 minutes
Immediately transfer serum into plastic vial
1.0 mL
0.5 - 1.0 mcg/mL
1.0 mcg/mL (combination of Diazepam and Nordiazepam))
Detect use • Evaluate therapeutic effect or possible toxicity
Diazepam (Valium®, Valrelease) is the second benzodiazepine derivative to have been approved for human usage (1963) and has been one of the most frequently prescribed drugs in the United States. It is administered as an antianxiety agent, muscle relaxant, or anticonvulsant, orally or by intramuscular or intravenous injection, in single doses of 2-20 mg and up to 40 mg daily. Diazepam undergoes N-demethylation to nordiazepam, a metabolite at least as active as its parent. Overdosage with diazepam generally results in drowsiness, ataxia, and muscular weakness. Chronic usage may cause physical dependence, and grand mal seizures can occur upon withdrawal.
3 to 5 days
00910376
80346